arrow
L

Lucia Fratino

centro di riferimento oncologico aviano
H指数:24
被引数:2,749

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Probe-Based Confocal Laser Endomicroscopy During Immune Checkpoint Inhibitor Therapy: A Translational Framework Linking Intestinal Barrier Function, Microbiota, and Clinical Outcomes

基于探针的共聚焦激光内窥镜在免疫检查点抑制剂治疗期间的应用:连接肠道屏障功能、微生物组和临床结局的转化研究框架

2026-09-210
OA
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma

国际多中心研究探讨转移性非透明细胞肾细胞癌的预后因素及治疗效果

2026-08-010
PRE
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients

LC-MS/MS法用于前列腺癌患者阿比特龙、达罗他胺、阿帕他胺、恩扎卢他胺及其代谢物的治疗药物监测

2026-03-290
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial

老年科医生实施的干预措施对早期或晚期实体瘤易感老年患者化疗(CT)给药的影响:GIVE试验

2024-09-010
PRE
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

mRCC骨转移患者的钠水平和免疫治疗功效: Meet-Uro 15研究的子分析

2024-07-055
OAAI
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

转移性前列腺癌老年患者日常生活的工具性活动: 来自meet-URO网络坚持前瞻性研究的结果

2024-02-281
OAAI
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

局部/局部晚期疾病的初始管理方法对于指导转移性去势抵抗性前列腺癌的治疗至关重要

2024-02-121
PRE
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

接受nivolumab治疗的转移性肾细胞癌患者的策略失败和治疗超过进展的时间: 对Meet-URO 15研究的事后分析

2024-02-121
OAAI
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

一项II期研究,评估恩扎鲁他胺的功效以及液体活检在评估包括内脏疾病在内的可测量转移的mCRPC患者中ARv7的作用 (Excalibur研究)

2024-01-221
OAAI
Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

接受nivolumab治疗的转移性肾细胞癌 (mRCC) 患者 (pts) 的治疗失败时间 (TTF) 和治疗超过进展 (TBP): 生存结果和临床获益的治疗策略 (meet-uro 15)

2023-10-011
OA
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023-07-013
OAAI
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

在意大利扩大访问计划中接受一线nivolumab和ipilimumab的转移性肾细胞癌患者中验证Meet-URO评分

2022-12-0121
OAAI
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

先前的肾切除术在接受免疫治疗的转移性肾细胞癌中的预后价值: 对Meet-URO 15研究的子分析

2022-09-3011
OAAI
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
2022-09-2311
OAAI
Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
2021-09-011
OA